ArticleAustralasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists2023
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.
Article in Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Autism, youth suicide, and psychedelics: A review of the 21st century evidence.Journal of the Chinese Medical Association : JCMA · 2024Pooled it
- Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights.Journal of psychopharmacology (Oxford, England) · 2026Article
- Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.The Australian and New Zealand journal of psychiatry · 2024Article
- A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.The Australian and New Zealand journal of psychiatry · 2024Review
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential.Molecular psychiatry · 2024Review
- Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".Global advances in integrative medicine and healthArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the knowledge and attitudes of psychiatrists about psychedelics therapies.
methodAccess to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions.
resultsFifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future.
conclusionConsidering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.